Alterity Therapeutics (ATHE) Net Cash Flow (2009 - 2020)

Alterity Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at -$6.2 million for Q2 2020.

• On a quarterly basis, Net Cash Flow rose 36.76% year-over-year to -$6.2 million in Q2 2020; TTM through Dec 2021 was -$6.2 million, a 55.94% increase from a year earlier, with the FY2025 full-year figure at $13.3 million, up 692.99% from the prior year.
• Net Cash Flow eased to -$6.2 million in Q2 2020 per ATHE's latest filing, from $1.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $1.9 million in Q4 2019 and bottomed at -$9.8 million in Q2 2019.
• The 5-year median for Net Cash Flow is -$4.4 million (2017), against an average of -$3.4 million.
• Biggest YoY gain for Net Cash Flow was 137.95% in 2019; the steepest drop was 20575.33% in 2019.
• Year by year, Net Cash Flow stood at -$598231.8 in 2016, then slumped by 56.04% to -$933486.7 in 2017, then sank by 444.27% to -$5.1 million in 2018, then surged by 137.95% to $1.9 million in 2019, then plunged by 420.59% to -$6.2 million in 2020.
• Per Business Quant, the three latest ATHE Net Cash Flow figures stand at -$6.2 million (Q2 2020), $1.9 million (Q4 2019), and -$9.8 million (Q2 2019).